Efficacy and safety of PCSK9 inhibitor for dyslipidemia

Efficacy and safety of PCSK9 inhibitor for dyslipidemia - EVOLUTION trial (effects of EVOLocUmab on lipid and oxidaTIve stress biOmarkers in high-risk patieNts with Cardiovascular disease)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023483

Enrollment

100

Registered

2016-08-04

Start date

2016-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory dyslipidemia

Interventions

PCSK9 inhibitor (repasa) for patients with refractory dyslipidemia 140mg/every 2 weeks for 24 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: refractory dyslipidemia

Exclusion criteria

Exclusion criteria: Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
LDL, HDL, T-cho(Pre, 1M, 3M, 6M, 1Y, 2Y)	—

Secondary

Measure	Time frame
Pre, 6M, 1Y, 2Y 1) FMD 2) carotis echo 3) ABI Pre, 3M, 6M, 1Y, 2Y 4) U-alb, U-type IV collagen 5) cystatin C, ox-LDL, Lp (a), EPA/AA, Apo A1, B, E, TG 6) Cr,eGFR 7) complications	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3982-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026